Today, Reuters Pharma USA 2026 kicks off in Philadelphia.
More than 1,500 senior pharma and biotech leaders — 87% Director level and above — are coming together for 2 days. Sessions will unpack the hardest problems in the industry across commercial strategy, market access, patient engagement, and AI at scale. With rare disease patients waiting an average of 5 years for a diagnosis, the urgency in that room is real. The conversations that matter start right now.
Here are 4 interesting topics on the agenda — and why they matter:
Scaling Commercial Insights with AI Agents — Regeneron’s Analytics Evolution
Regeneron’s team is on stage sharing how AI Agents — that perform analysis, not just assist — answered “What, Why, and How” faster than any legacy analytics tool ever could. The analyst queue is being replaced by governed, auditable, instant answers.
Rare Disease Launch Success: A Playbook for Building Trust and Driving Adoption
UCB, AstraZeneca, and KalVista Pharmaceuticals are unpacking how to engage rare disease patients, caregivers, and HCPs with empathy — and how AI combined with human understanding optimizes targeting and personalizes experiences for rare disease brands.
Agentic AI for HCP Engagement at Scale
How agentic AI helps teams move from manual orchestration to coordinated execution — using intelligent agents to streamline content planning, compliant versioning, channel activation, and performance optimization. The shift from doing things manually to agents doing them autonomously is no longer a future concept.
From AI Agents to Invisible Intelligence: The Next Operating Model for Pharma
The next frontier is not discrete AI agents — it is embedded, ambient intelligence woven directly into core commercial systems. Human-in-the-loop triggers keep teams in control while agents automate repeatable tasks and drive consistent, high-quality execution at scale.
At Clinakos, we built Clarion™ specifically for this. Our AI Research Agent navigates real, consented patient journeys across 1,500+ rare disease and oncology panels — turning complex research questions into high-fidelity insights in minutes, not months.
